SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Somatogen (SMTG) -- Ignore unavailable to you. Want to Upgrade?


To: Bharat H. Barai who wrote (401)2/24/1998 10:05:00 AM
From: CarlPerf  Respond to of 442
 
Merger annoucement,

Strategically, this is a golden investment opportunity for Baxter. They are acquiring a biotech firm with tremendous potential. Unfortunately, I believe the stock is worth twice what Baxter is offering. Knowing Baxter's negotiating prowess, I believe this represents a "done deal" and other offers will not be forthcoming. Personally, I would not hold Baxter shares and will tender my small holdings in Somatogen.
It is a true irony of life - on the day I join this thread to interact with Somatogen believers, they release an acqusition announcement. Such is life in this topsy/turvy investment world. Good fortunes to all SMTG shareholders.



To: Bharat H. Barai who wrote (401)2/24/1998 10:25:00 AM
From: aknahow  Read Replies (1) | Respond to of 442
 
Dr.Barai, thank you for your many fine post. I agree with you even though my most recent purchases were at an effective cost of about $4.20.

What is really sad is that then news was leaked. I have never been called by my broker to be asked if I wanted to sell additional calls. Was lucky to have a small residual holding of shares. Someone actually posted on Yahoo stock would rise to $9 in few weeks.

However the clues were there. Co was saying, "we are talking about getting married, talks are going as expected. Don't know to whom but wedding is fixed before end of second quarter." Baxter now also committed to that date.